North America Pharmaceutical Manufacturing Industry Outlook, 2029

The North America Pharmaceutical Manufacturing Industry expected to reach USD 612.5 billion, driven by rise in disposable income.

According to publisher, North America is a titan in the global pharmaceutical manufacturing industry, boasting innovation and a robust infrastructure. This report explores the market's value, growth drivers, dynamics, segmentation, regional variations within North America, key trends, and the competitive landscape. Market Insights:

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

Market Value and Growth: The North American pharmaceutical manufacturing industry is a multi-billion dollar powerhouse, expected to reach USD 612.5 billion. This growth is fueled by factors like: High Healthcare Spending: North America spends a significant portion of its GDP on healthcare, with a large allocation dedicated to pharmaceuticals. Example: The US government's Medicare and Medicaid programs provide substantial funding for prescription drugs. Aging Population: A rapidly growing elderly population in North America increases demand for medications to manage chronic conditions. Example: Increased production of drugs for Alzheimer's disease and age-related macular degeneration. Market Dynamics

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant

The North American market is a dynamic environment influenced by several key trends: Focus on Innovation: North American pharmaceutical companies invest heavily in research and development (R&D) to create new and innovative drugs. Example: The development of mRNA vaccines, like those used for COVID-19, showcases North American innovation in drug discovery. Balancing Cost and Affordability: Rising healthcare costs and concerns about drug affordability are major challenges. Companies are exploring ways to balance innovation with affordability. Example: Generic drug manufacturers offer cost-effective alternatives to brand-name medications once patents expire.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval

Strict Regulatory Environment: The US Food and Drug Administration (FDA) enforces strict regulations to ensure the safety and efficacy of drugs manufactured in North America. Example: Pharmaceutical companies must undergo rigorous clinical trials before receiving FDA approval to market a new drug. Market Segments The North American market can be segmented based on various criteria: Product Type: The industry manufactures a wide range of products, including prescription drugs, over-the-counter medications, vaccines, and biopharmaceuticals. Therapeutic Area: Drugs are developed to target specific therapeutic areas like oncology (cancer), cardiology (heart disease), and neurology (brain disorders). Regional Analysis While North America functions as a single market, there are variations: The United States: The United States is the dominant player due to its large pharmaceutical industry, strong R&D infrastructure, and high healthcare spending. Example: Many leading pharmaceutical companies and research institutions are headquartered in the US. Canada: Canada has a smaller but well-developed pharmaceutical manufacturing sector with a focus on biologics and generic drugs. Example: Canadian companies are playing a significant role in the production of biosimilar drugs, which are similar to brand-name biologics but more affordable. Key Developments The North American market is experiencing continuous innovation: Advanced Manufacturing Technologies: Companies are adopting advanced manufacturing technologies like continuous manufacturing to improve efficiency and reduce production costs. Example: Continuous manufacturing allows for uninterrupted drug production, minimizing waste and increasing output. Focus on Nearshoring: Concerns about global supply chain disruptions are leading to a trend of nearshoring, where drug manufacturing is shifted to facilities closer to North America. Example: Pharmaceutical companies might establish manufacturing plants in Mexico or other Central American countries to reduce reliance on overseas production facilities. Competitive Landscape The North American pharmaceutical manufacturing industry is a competitive landscape with established players and emerging companies: Big Pharma: Large multinational pharmaceutical companies dominate the market with a strong presence in research, development, and manufacturing. Example: Companies like Pfizer, Merck, and Johnson & Johnson hold significant market share and invest heavily in R&D. Biotechnology Companies: Biotechnology companies specializing in cutting-edge therapies like gene editing and gene therapies are gaining traction. Example: Smaller biotech companies might partner with Big Pharma for large-scale production of their innovative drugs. Contract Manufacturing Organizations (CMOs): CMOs provide manufacturing services to pharmaceutical companies, allowing them to focus on core competencies like drug discovery and development. Example: A pharmaceutical company might partner with a CMO to manufacture a new drug while they focus on developing the next generation of treatments. Conclusion The North American pharmaceutical manufacturing industry plays a vital role in global health advancements. With a focus on innovation, affordability, and advanced manufacturing technologies, North America is poised to remain a leader in this ever-evolving sector.

Table of Contents

  • 1 Introduction 9
  • 1.1 Industry Definition and Research Scope 9
  • 1.1.1 Industry Definition 9
  • 1.1.2 Research Scope 10
  • 1.2 Research Methodology 13
  • 1.2.1 Overview of Market Research Methodology 13
  • 1.2.2 Market Assumption 14
  • 1.2.3 Secondary Data 14
  • 1.2.4 Primary Data 14
  • 1.2.5 Data Filtration and Model Design 15
  • 1.2.6 Market Size/Share Estimation 16
  • 1.2.7 Research Limitations 17
  • 1.3 Executive Summary 18
  • 2 Market Overview and Dynamics 21
  • 2.1 Market Size and Forecast 21
  • 2.1.1 Impact of COVID-19 on World Economy 24
  • 2.1.2 Impact of COVID-19 on the Market 27
  • 2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 29
  • 2.2 Major Growth Drivers 33
  • 2.3 Market Restraints and Challenges 40
  • 2.4 Emerging Opportunities and Market Trends 43
  • 2.5 Porter’s Fiver Forces Analysis 47
  • 3 Segmentation of North America Market by Formulation 51
  • 3.1 Market Overview by Formulation 51
  • 3.2 Tablets 53
  • 3.3 Capsules 54
  • 3.4 Injectable 55
  • 3.5 Sprays 56
  • 3.6 Suspensions 57
  • 3.7 Powders 58
  • 3.8 Other Formulations 59
  • 4 Segmentation of North America Market by Route of Administration 60
  • 4.1 Market Overview by Route of Administration 60
  • 4.2 Oral Medicine 62
  • 4.3 Topical Medicine 63
  • 4.4 Parenteral Medicine 64
  • 4.5 Inhalations 65
  • 4.6 Other Routes of Administration 66
  • 5 Segmentation of North America Market by Consumer Group 67
  • 5.1 Market Overview by Consumer Group 67
  • 5.2 Children & Adolescents (17 years old and below) 69
  • 5.3 Adults (18-64 years old) 70
  • 5.4 Geriatric (65 years old and above) 71
  • 6 Segmentation of North America Market by Therapeutic Application 72
  • 6.1 Market Overview by Therapeutic Application 72
  • 6.2 Cardiovascular Diseases 74
  • 6.3 Pain 75
  • 6.4 Diabetes 76
  • 6.5 Cancer 77
  • 6.6 Respiratory Diseases 78
  • 6.7 Neurological Diseases 79
  • 6.8 Orthopedics 80
  • 6.9 Other Applications 81
  • 7 Segmentation of North America Market by Drug Type 82
  • 7.1 Market Overview by Drug Type 82
  • 7.2 Branded Prescription Drugs 84
  • 7.3 Generic Prescription Drugs 85
  • 7.4 OTC Drugs 86
  • 8 Segmentation of North America Market by Distribution Channel 87
  • 8.1 Market Overview by Distribution Channel 87
  • 8.2 Retail Channels 89
  • 8.3 Non-retail Channels 90
  • 9 Segmentation of North America Market by Manufacturing Facility 91
  • 9.1 Market Overview by Manufacturing Facility 91
  • 9.2 In-house Facility 93
  • 9.3 Outsourced Facility 94
  • 10 North America Market 2022-2032 by Country 95
  • 10.1 Overview of North America Market 95
  • 10.2 U.S. 98
  • 10.3 Canada 105
  • 10.4 Mexico 107
  • 11 Competitive Landscape 109
  • 11.1 Overview of Key Vendors 109
  • 11.2 New Product Launch, Partnership, Investment, and M&A 112
  • 11.3 Company Profiles 113
  • Abbott Laboratories 113
  • Aenova Group 115
  • Amgen Inc. 119
  • AstraZeneca 122
  • Catalent Inc. 125
  • Eli Lilly and Company 128
  • F. Hoffmann-La Roche Ltd. 130
  • Gilead Sciences Inc. 132
  • GlaxoSmithKline plc 134
  • Johnson & Johnson 138
  • Lonza Group 140
  • Lupin Limited 143
  • Merck & Co., Inc. 145
  • Novartis AG 147
  • Novo Nordisk 149
  • Patheon Inc. 152
  • Pfizer CentreSource 156
  • Sanofi SA 160
  • Takeda 162
  • RELATED REPORTS 164



Table 1. Snapshot of North America Pharmaceutical Manufacturing Industry in Balanced Perspective, 2022-2032 19
Table 2. World Pharmaceuticals Output by Region, 2022-2025, annual percentage change 23
Table 3. World Economic Outlook, 2021-2031 25
Table 4. World Economic Outlook, 2021-2023 26
Table 5. Scenarios for Economic Impact of Ukraine Crisis 30
Table 6. World Health Spending by Region, $ bn, 2013-2020 39
Table 7. Main Product Trends and Market Opportunities in North America Pharmaceutical Manufacturing Industry 43
Table 8. North America Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 51
Table 9. North America Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 60
Table 10. North America Pharmaceutical Manufacturing Industry by Consumer Group, 2022-2032, $ mn 67
Table 11. North America Pharmaceutical Manufacturing Industry by Therapeutic Application, 2022-2032, $ mn 72
Table 12. North America Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 82
Table 13. North America Pharmaceutical Manufacturing Industry by Distribution Channel, 2022-2032, $ mn 87
Table 14. North America Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2022-2032, $ mn 91
Table 15. North America Pharmaceutical Manufacturing Industry by Country, 2022-2032, $ mn 96
Table 16. U.S. Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 100
Table 17. U.S. Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 100
Table 18. U.S. Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 100
Table 19. Canada Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 106
Table 20. Canada Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 106
Table 21. Canada Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 106
Table 22. Mexico Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 108
Table 23. Mexico Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 108
Table 24. Mexico Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 108
Table 25. Abbott Laboratories: Company Snapshot 113
Table 26. Abbott Laboratories: Business Segmentation 114
Table 27. Abbott Laboratories: Product Portfolio 114
Table 28. Aenova Group: Company Snapshot 115
Table 29. Aenova Group: Business Segmentation 116
Table 30. Aenova Group: Revenue by Product, 2018-2019, thousand Euro 117
Table 31. Aenova Group: Recent Developments 118
Table 32. Amgen Inc.: Company Snapshot 119
Table 33. Amgen Inc.: Approved Drugs or Therapeutic Biologicals 120
Table 34. Astrazeneca: Company Snapshot 122
Table 35. Catalent Inc.: Company Snapshot 125
Table 36. Catalent Inc.: Business Segmentation in 2018 126
Table 37. Catalent Inc.: Product Portfolio 126
Table 38. Catalent Inc.: Revenue, 2018-2020, $ million 127
Table 39. Catalent Inc.: Revenue by Region in 2018 127
Table 40. Eli Lilly and Company: Company Snapshot 128
Table 41. Eli Lilly and Company: Pharmaceutical Brands 129
Table 42. F. Hoffmann-La Roche: Company Snapshot 130
Table 43. F. Hoffmann-La Roche: Business Segmentation 130
Table 44. F. Hoffmann-La Roche: Revenue, 2017-2019, $ bn 131
Table 45. Gilead Sciences: Company Snapshot 132
Table 46. Gilead Sciences: Main Products 132
Table 47. GlaxoSmithKline: Company Snapshot 134
Table 48. GlaxoSmithKline: Business Segmentation 135
Table 49. GlaxoSmithKline: Product Portfolio 136
Table 50. GlaxoSmithKline: Revenue, 2018-2020, $ bn 137
Table 51. Johnson & Johnson: Company Snapshot 138
Table 52. Johnson & Johnson: Business Segments 138
Table 53. Lonza Group: Company Snapshot 140
Table 54. Lonza Group: Business Segmentation in 2018 140
Table 55. Lonza Group: Product Portfolio 141
Table 56. Lonza Group: Revenue by Region in 2018 141
Table 57. Lupin Limited: Company Snapshot 143
Table 58. Lupin Limited: Business Segmentation 144
Table 59. Merck & Co., Inc.: Company Snapshot 145
Table 60. Merck & Co., Inc.: Business Segmentation 145
Table 61. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 146
Table 62. Novartis International AG: Company Snapshot 147
Table 63. Novartis International AG: Business Segmentation 147
Table 64. Novartis International AG: Revenue, 2017-2019, $ bn 148
Table 65. Novo Nordisk: Company Snapshot 149
Table 66. Novo Nordisk: Product Portfolio 150
Table 67. Patheon Inc.: Company Snapshot 152
Table 68. Patheon Inc.: Business Segmentation in 2018 153
Table 69. Patheon Inc.: Product Portfolio 153
Table 70. Patheon Inc.: Revenue, 2017-2019, $ billion 154
Table 71. Patheon Inc.: Revenue by Region in 2018 154
Table 72. Patheon Inc.: Recent Developments 155
Table 73. Pfizer CentreSource: Company Snapshot 156
Table 74. Pfizer CentreSource: Business Segmentation in 2018 157
Table 75. Pfizer CentreSource: Product Portfolio 157
Table 76. Pfizer CentreSource: Revenue, 2017-2019, $ billion 158
Table 77. Pfizer CentreSource: Revenue by Region in 2018 158
Table 78. Hospira, Inc. (a subsidiary of Pfizer): Company Snapshot 158
Table 79. Pfizer CentreSource: Recent Developments 159
Table 80. Sanofi: Company Snapshot 160
Table 81. Sanofi: Business Segmentation 160
Table 82. Sanofi: Revenue, 2018-2020, $ bn 161
Table 83. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 162



Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032 18
Figure 4. North America Pharmaceutical Manufacturing Industry, 2022-2032, $ mn 21
Figure 5. World Healthcare Services Production, annual percentage change 23
Figure 6. Impact of COVID-19 on Business 27
Figure 7. Primary Drivers and Impact Factors of North America Pharmaceutical Manufacturing Industry 33
Figure 8. Trends in the Approval of Cancer Therapies by FDA in the Twenty-First Century 36
Figure 9. Leading Causes of Death in the World, 2000 and 2019, million 37
Figure 10. Worldwide Geriatric Population (60 years and above) by Region, 2015 & 2030, million 38
Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 38
Figure 12. Primary Restraints and Impact Factors of North America Pharmaceutical Manufacturing Industry 40
Figure 13. Investment Opportunity Analysis 44
Figure 14. Porter’s Fiver Forces Analysis of North America Pharmaceutical Manufacturing Industry 47
Figure 15. Breakdown of North America Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, % of Revenue 52
Figure 16. North America Addressable Market Cap in 2023-2032 by Formulation, Value ($ mn) and Share (%) 52
Figure 17. North America Pharmaceutical Manufacturing Industry by Formulation: Tablets, 2022-2032, $ mn 53
Figure 18. North America Pharmaceutical Manufacturing Industry by Formulation: Capsules, 2022-2032, $ mn 54
Figure 19. North America Pharmaceutical Manufacturing Industry by Formulation: Injectable, 2022-2032, $ mn 55
Figure 20. North America Pharmaceutical Manufacturing Industry by Formulation: Sprays, 2022-2032, $ mn 56
Figure 21. North America Pharmaceutical Manufacturing Industry by Formulation: Suspensions, 2022-2032, $ mn 57
Figure 22. North America Pharmaceutical Manufacturing Industry by Formulation: Powders, 2022-2032, $ mn 58
Figure 23. North America Pharmaceutical Manufacturing Industry by Formulation: Other Formulations, 2022-2032, $ mn 59
Figure 24. Breakdown of North America Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, % of Sales Revenue 61
Figure 25. North America Addressable Market Cap in 2023-2032 by Route of Administration, Value ($ mn) and Share (%) 61
Figure 26. North America Pharmaceutical Manufacturing Industry by Route of Administration: Oral Medicine, 2022-2032, $ mn 62
Figure 27. North America Pharmaceutical Manufacturing Industry by Route of Administration: Topical Medicine, 2022-2032, $ mn 63
Figure 28. North America Pharmaceutical Manufacturing Industry by Route of Administration: Parenteral Medicine, 2022-2032, $ mn 64
Figure 29. North America Pharmaceutical Manufacturing Industry by Route of Administration: Inhalations, 2022-2032, $ mn 65
Figure 30. North America Pharmaceutical Manufacturing Industry by Route of Administration: Other Routes of Administration, 2022-2032, $ mn 66
Figure 31. Breakdown of North America Pharmaceutical Manufacturing Industry by Consumer Group, 2022-2032, % of Sales Revenue 68
Figure 32. North America Addressable Market Cap in 2023-2032 by Consumer Group, Value ($ mn) and Share (%) 68
Figure 33. North America Pharmaceutical Manufacturing Industry by Consumer Group: Children & Adolescents (17 years old and below), 2022-2032, $ mn 69
Figure 34. North America Pharmaceutical Manufacturing Industry by Consumer Group: Adults (18-64 years old), 2022-2032, $ mn 70
Figure 35. North America Pharmaceutical Manufacturing Industry by Consumer Group: Geriatric (65 years old and above), 2022-2032, $ mn 71
Figure 36. Breakdown of North America Pharmaceutical Manufacturing Industry by Therapeutic Application, 2022-2032, % of Revenue 73
Figure 37. North America Addressable Market Cap in 2023-2032 by Therapeutic Application, Value ($ mn) and Share (%) 73
Figure 38. North America Pharmaceutical Manufacturing Industry by Therapeutic Application: Cardiovascular Diseases, 2022-2032, $ mn 74
Figure 39. North America Pharmaceutical Manufacturing Industry by Therapeutic Application: Pain, 2022-2032, $ mn 75
Figure 40. North America Pharmaceutical Manufacturing Industry by Therapeutic Application: Diabetes, 2022-2032, $ mn 76
Figure 41. North America Pharmaceutical Manufacturing Industry by Therapeutic Application: Cancer, 2022-2032, $ mn 77
Figure 42. North America Pharmaceutical Manufacturing Industry by Therapeutic Application: Respiratory Diseases, 2022-2032, $ mn 78
Figure 43. North America Pharmaceutical Manufacturing Industry by Therapeutic Application: Neurological Diseases, 2022-2032, $ mn 79
Figure 44. North America Pharmaceutical Manufacturing Industry by Therapeutic Application: Orthopedics, 2022-2032, $ mn 80
Figure 45. North America Pharmaceutical Manufacturing Industry by Therapeutic Application: Other Applications, 2022-2032, $ mn 81
Figure 46. Breakdown of North America Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, % of Revenue 83
Figure 47. North America Addressable Market Cap in 2023-2032 by Drug Type, Value ($ mn) and Share (%) 83
Figure 48. North America Pharmaceutical Manufacturing Industry by Drug Type: Branded Prescription Drugs, 2022-2032, $ mn 84
Figure 49. North America Pharmaceutical Manufacturing Industry by Drug Type: Generic Prescription Drugs, 2022-2032, $ mn 85
Figure 50. North America Pharmaceutical Manufacturing Industry by Drug Type: OTC Drugs, 2022-2032, $ mn 86
Figure 51. Breakdown of North America Pharmaceutical Manufacturing Industry by Distribution Channel, 2022-2032, % of Revenue 87
Figure 52. North America Addressable Market Cap in 2023-2032 by Distribution Channel, Value ($ mn) and Share (%) 88
Figure 53. North America Pharmaceutical Manufacturing Industry by Distribution Channel: Retail Channels, 2022-2032, $ mn 89
Figure 54. North America Pharmaceutical Manufacturing Industry by Distribution Channel: Non-retail Channels, 2022-2032, $ mn 90
Figure 55. Breakdown of North America Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2022-2032, % of Revenue 91
Figure 56. North America Addressable Market Cap in 2023-2032 by Manufacturing Facility, Value ($ mn) and Share (%) 92
Figure 57. North America Pharmaceutical Manufacturing Industry by Manufacturing Facility: In-house Facility, 2022-2032, $ mn 93
Figure 58. North America Pharmaceutical Manufacturing Industry by Manufacturing Facility: Outsourced Facility, 2022-2032, $ mn 94
Figure 59. Breakdown of North America Pharmaceutical Manufacturing Industry by Country, 2022 and 2032, % of Revenue 96
Figure 60. Contribution to North America 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%) 97
Figure 61. U.S. Pharmaceutical Manufacturing Industry, 2022-2032, $ mn 99
Figure 62. Sources of API Manufacturing by Product Area in U.S., as of May 2021 101
Figure 63. Manufacturing Locations of Essential Medicines in U.S., as of May 2021 102
Figure 64. Count of High-Capacity API Sites in U.S. in 2021 103
Figure 65. FDA-Approved API Manufacturing Sites in U.S., 2016-2021 104
Figure 66. Canada Pharmaceutical Manufacturing Industry, 2022-2032, $ mn 105
Figure 67. Pharmaceutical Manufacturing Industry in Mexico, 2022-2032, $ mn 107
Figure 68. Growth Stage of North America 3D Printing Industry over the Forecast Period 109
Figure 69. Top products of AstraZeneca based on revenue from 2016 to 2019 (in million U.S. dollars) 123
Logo

North America Pharmaceutical Manufacturing Industry Outlook, 2029

Contact usWe are friendly and approachable, give us a call.